The microbial world has been a rich source of medicines, but our ability to explore the full potential of the microbes both in us and around us has been limited by technology and the difficulty of culturing most microbes in a lab. Biosortia Microbiomics has developed a platform for finding, amplifying, and screening microbes as a potential source of novel, small molecule drugs. We spoke to Ross Youngs, CEO and founder of Biosortia, about the case for exploring various microbiomes to discover new small molecule drugs, how the company’s platform technology enables it to investigate a much broader range of microbes, and its business model for capitalizing on the discoveries it makes.
Using a Digital Cognitive Behavior Therapy to Treat Diabetes and Heart Disease
Disrupting Pain Signals with Precision
A Diagnostics Company Moves to Developing Precision Cancer Therapies
Characterizing the Immunome at Scale
Delivering Oxygen to Tissue in Need
Using Gene Therapy to Create a Drug Biofactory within a Patient
Finding New Uses for TNF Inhibitors
Using AI to Map the Undiscovered World of Bioactive Compounds in Plants
Improving the Delivery of Drugs through Thin Film Freezing
Using CRISPR to Target RNA Instead of DNA
An Antisense Pioneer Brings Custom Treatments to Patients with Ultra-Rare Conditions
Managing Neurodegenerative Diseases with Better Data to Improve Outcomes
A Small Molecule Cancer Drug That Promotes an Adaptive Immune Response
Sloan-Kettering Spin-Out Harnesses AI to Diagnose Cancer
Bringing Innovation to Cell and Gene Therapy Manufacturing
Tapping Psychedelics for their Anti-Inflammatory Powers
Advancing Cell Therapies Beyond Cancer
How the Pandemic Transformed a Small Diagnostics Company
Eliminating Security, Privacy, and Regulatory Burdens with Synthetic Data
Using Computational Discovery to Build Better Immunotherapies
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
All In The Mind